# US 2002/0058783 A1 · Fibroblast growth factor 14

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0058783 A1
- Document ID: US20020058783A1
- Status: Published application
- Kind: A1
- Application number: 08/462,159
- Filed: 1995-06-05
- Published: 2002-05-16
- Earliest claimed: 1995-06-05
- Assignees: Human Genome Sciences, Inc.
- Inventors: JOHN M. GREENE; PATRICK J. DILLON
- Web page: https://patentgrep.com/patent/US20020058783A1

## CPC

- C07K 14/50: Fibroblast growth factor [FGF]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2799/026: where the vector is derived from a baculovirus
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed is a human Fibroblast growth factor-14 polypeptide and DNA(RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques. Also disclosed are methods for utilizing such polypeptide for promoting wound healing for example as a result of burns and ulcers, to prevent neuronal damage due to associated with stroke and promote neuronal growth, and to prevent skin aging and hair loss, to stimulate angiogenesis, mesodermal induction in early embryos and limb regeneration. Antagonists against such polypeptides and their use as a therapeutic to prevent abnormal cellular proliferation, hyper-vascular diseases and epithelial lens cell proliferation are also disclosed. Diagnostic methods for detecting mutations in the coding sequence and alterations in the concentration of the polypeptides in a sample derived from a host are also disclosed.

## Claims

### Claim 1

An isolated polynucleotide comprising a member selected from the group consisting of:
(a) a polynucleotide encoding the polypeptide comprising amino acid −26 to amino acid 199 as set forth in SEQ ID NO:2;
(b) a polynucleotide encoding the polypeptide comprising amino acid 1 to amino acid 199 as set forth in SEQ ID no:2;
(c) a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a) or (b); and
(d) a polynucleotide fragment of the polynucleotide of (a), (b) or (c).

### Claim 2 (depends on 1)

The polynucleotide of claim 1 wherein the polynucleotide is DNA.

### Claim 3 (depends on 1)

The polynucleotide of claim 1 comprising from nucleotide 1 to nucleotide 680 as set forth in SEQ ID NO: 1.

### Claim 4 (depends on 1)

The polynucleotide of claim 1 comprising from nucleotide 79 to nucleotide 680 as set forth in SEQ ID NO:1.

### Claim 5

An isolated polynucleotide comprising a member selected from the group consisting of:
(a) a polynucleotide encoding a mature polypeptide encoded by the DNA contained in ATCC Deposit No. 97148;
(b) a polynucleotide encoding the polypeptide expressed by the DNA contained in ATCC Deposit No. 97148;
(c) a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a) or (b); and
(d) a polynucleotide fragment of the polynucleotide of
(a), (b) or (c).

### Claim 6 (depends on 2)

A vector containing the DNA of claim 2.

### Claim 7 (depends on 6)

A host cell genetically engineered with the vector of claim 6.

### Claim 8 (depends on 7)

A process for producing a polypeptide comprising:
expressing from the host cell of claim 7 the polypeptide encoded by said DNA.

### Claim 9 (depends on 6)

A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of claim 6.

### Claim 10

A polypeptide comprising a member selected from the group consisting of (i) a polypeptide having the deduced amino acid sequence of SEQ ID NO:2 and fragments, analogs and derivatives thereof; and (ii) a polypeptide encoded by the cDNA of ATCC Deposit No. 97148 and fragments, analogs and derivatives of said polypeptide.

### Claim 11 (depends on 10)

An antibody against the polypeptide of claim 10.

### Claim 12 (depends on 10)

A compound which inhibits the biological actions of the polypeptide of claim 10.

### Claim 13 (depends on 10)

A compound which activates a receptor to the polypeptide of claim 10.

### Claim 14 (depends on 10)

A method for the treatment of a patient having need of an FGF-14 polypeptide comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 10.

### Claim 15 (depends on 12)

A method for,the treatment of a patient having need to inhibit an FGF-14 polypeptide comprising: administering to the patient a therapeutically effective amount of the compound of claim 12.

### Claim 16 (depends on 14)

The method of claim 14 wherein said therapeutically effective amount of said polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.

### Claim 17 (depends on 15)

The method of claim 15 wherein said compound is a polypeptide and a therapeutically effective amount of the compound is administered by providing to the patient DNA encoding said antagonist and expressing said antagonist in vivo.

### Claim 18 (depends on 10)

A process for identifying compounds active as agonists to the polypeptide of claim 10 comprising:
(a) combining a compound to be screened and a reaction mixture containing cells under conditions where the cells are normally stimulated by said polypeptide, said reaction mixture containing a label incorporated into the cells as they proliferate; and
(b) determining the extent of proliferation of the cells to identify if the compound is an effective agonist.

### Claim 19 (depends on 10)

A process for identifying compounds active as antagonists to the polypeptide of claim 10 comprising:
(a) combining a compound to be screened, the polypeptide and a reaction mixture containing cells under conditions where the cells are normally stimulated by said polypeptide, said reaction mixture containing a label incorporated into the cells as they proliferate; and
(b) determining the extent of proliferation of the cells to identify if the compound is an effective antagonist.

### Claim 20 (depends on 10)

A process for diagnosing a disease or a susceptibility to a disease related to an under-expression of the polypeptide of claim 10 comprising:
determining a mutation in the nucleic acid sequence encoding said polypeptide.
